201 related articles for article (PubMed ID: 34461940)
1. GSK2126458 has the potential to inhibit the proliferation of pancreatic cancer uncovered by bioinformatics analysis and pharmacological experiments.
Feng Y; Jiang Y; Hao F
J Transl Med; 2021 Aug; 19(1):373. PubMed ID: 34461940
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
Leung E; Kim JE; Rewcastle GW; Finlay GJ; Baguley BC
Cancer Biol Ther; 2011 Jun; 11(11):938-46. PubMed ID: 21464613
[TBL] [Abstract][Full Text] [Related]
3. Screening and validating the core biomarkers in patients with pancreatic ductal adenocarcinoma.
Li Y; Zhu YY; Dai GP; Wu DJ; Gao ZZ; Zhang L; Fan YH
Math Biosci Eng; 2019 Nov; 17(1):910-927. PubMed ID: 31731384
[TBL] [Abstract][Full Text] [Related]
4. Screening and identification of hub genes in pancreatic cancer by integrated bioinformatics analysis.
Chen Q; Yu D; Zhao Y; Qiu J; Xie Y; Tao M
J Cell Biochem; 2019 Dec; 120(12):19496-19508. PubMed ID: 31297881
[TBL] [Abstract][Full Text] [Related]
5. Integrated bioinformatics analysis of potential biomarkers for pancreatic cancer.
Shi H; Xu H; Chai C; Qin Z; Zhou W
J Clin Lab Anal; 2022 May; 36(5):e24381. PubMed ID: 35403252
[TBL] [Abstract][Full Text] [Related]
6. Down-regulated microRNA-223 or elevated ZIC1 inhibits the development of pancreatic cancer via inhibiting PI3K/Akt/mTOR signaling pathway activation.
Zhu J; Lv J; Chen J; Zhang X; Ji Y
Cell Cycle; 2020 Nov; 19(21):2851-2865. PubMed ID: 33064959
[No Abstract] [Full Text] [Related]
7. Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF.
Mercer PF; Woodcock HV; Eley JD; Platé M; Sulikowski MG; Durrenberger PF; Franklin L; Nanthakumar CB; Man Y; Genovese F; McAnulty RJ; Yang S; Maher TM; Nicholson AG; Blanchard AD; Marshall RP; Lukey PT; Chambers RC
Thorax; 2016 Aug; 71(8):701-11. PubMed ID: 27103349
[TBL] [Abstract][Full Text] [Related]
8. Identification of hub genes and regulators associated with pancreatic ductal adenocarcinoma based on integrated gene expression profile analysis.
Shang M; Zhang L; Chen X; Zheng S
Discov Med; 2019 Sep; 28(153):159-172. PubMed ID: 31926587
[TBL] [Abstract][Full Text] [Related]
9. Key genes associated with pancreatic cancer and their association with outcomes: A bioinformatics analysis.
Wu J; Li Z; Zeng K; Wu K; Xu D; Zhou J; Xu L
Mol Med Rep; 2019 Aug; 20(2):1343-1352. PubMed ID: 31173193
[TBL] [Abstract][Full Text] [Related]
10. A study on the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through PI3K/AKT/mTOR signaling pathway.
Li B; Yang J; Lu Z; Liu B; Liu F
J BUON; 2019; 24(2):739-745. PubMed ID: 31128031
[TBL] [Abstract][Full Text] [Related]
11. PI3K/mTOR inhibitors promote G6PD autophagic degradation and exacerbate oxidative stress damage to radiosensitize small cell lung cancer.
Deng H; Chen Y; Wang L; Zhang Y; Hang Q; Li P; Zhang P; Ji J; Song H; Chen M; Jin Y
Cell Death Dis; 2023 Oct; 14(10):652. PubMed ID: 37802999
[TBL] [Abstract][Full Text] [Related]
12. Integrative analysis of epigenomics, transcriptomics, and proteomics to identify key targets and pathways of Weining granule for gastric cancer.
Liang MK; Liang XQ; Zhong J; Wei YT; Lian ZP; Huang ZK; Liang J
J Ethnopharmacol; 2021 Apr; 270():113787. PubMed ID: 33422657
[TBL] [Abstract][Full Text] [Related]
13. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma.
Liu T; Sun Q; Li Q; Yang H; Zhang Y; Wang R; Lin X; Xiao D; Yuan Y; Chen L; Wang W
Mol Cancer Ther; 2015 Feb; 14(2):429-39. PubMed ID: 25504751
[TBL] [Abstract][Full Text] [Related]
14. ITGA2, LAMB3, and LAMC2 may be the potential therapeutic targets in pancreatic ductal adenocarcinoma: an integrated bioinformatics analysis.
Islam S; Kitagawa T; Baron B; Abiko Y; Chiba I; Kuramitsu Y
Sci Rep; 2021 May; 11(1):10563. PubMed ID: 34007003
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
[TBL] [Abstract][Full Text] [Related]
16. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
17. Identification of hub genes and analysis of prognostic values in pancreatic ductal adenocarcinoma by integrated bioinformatics methods.
Lu Y; Li C; Chen H; Zhong W
Mol Biol Rep; 2018 Dec; 45(6):1799-1807. PubMed ID: 30173393
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of abnormal expression, prognostic value and oncogenic role of the hub gene FN1 in pancreatic ductal adenocarcinoma
Lei X; Chen G; Li J; Wen W; Gong J; Fu J
PeerJ; 2021; 9():e12141. PubMed ID: 34567847
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells.
Xu Z; Zhang Y; Jiang J; Yang Y; Shi R; Hao B; Zhang Z; Huang Z; Kim JW; Zhang G
BMC Cancer; 2010 Apr; 10():161. PubMed ID: 20423485
[TBL] [Abstract][Full Text] [Related]
20. Desumoylating Isopeptidase 2 (DESI2) Inhibits Proliferation and Promotes Apoptosis of Pancreatic Cancer Cells through Regulating PI3K/AKT/mTOR Signaling Pathway.
Ou X; Zhang GT; Xu Z; Chen JS; Xie Y; Liu JK; Liu XP
Pathol Oncol Res; 2019 Apr; 25(2):635-646. PubMed ID: 30411297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
